Eldridge George A 4
4 · Aerovate Therapeutics, Inc. · Filed Apr 3, 2024
Insider Transaction Report
Form 4
Eldridge George A
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-04-01$2.14/sh+12,495$26,739→ 14,455 total - Sale
Common Stock
2024-04-01$31.23/sh−12,495$390,208→ 1,960 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-01−12,495→ 15,768 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (12,495 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.